Skip to main content
. Author manuscript; available in PMC: 2020 Dec 15.
Published in final edited form as: Cancer Cell. 2020 Aug 20;38(4):454–472. doi: 10.1016/j.ccell.2020.07.013

Figure 2. Examples of Durable Tumor Regressions in Patients Who Were Treated with TILs That Recognized Tumor Neoantigens.

Figure 2.

(A) Regression of lung tumors in a patient with metastatic colorectal carcinoma who received KRASG12D-reactive TILs. The tumor in the second row exhibited a partial response and was surgically resected; the pathology showed no viable tumor cells. The tumor in the third row progressed 9 months after the therapy and was then surgically resected. The pathology demonstrated loss of the MHC molecule necessary for the presentation of the KRASG12D.

(B) Complete regression of a chest wall mass (upper panels) and multiple liver tumors (lower panels) in a patient with metastatic breast cancer who received TILs directed against four different tumor mutations.